Biomarkers for Event-driven PrEP Adherence

PHASE4CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

February 28, 2020

Primary Completion Date

August 9, 2022

Study Completion Date

August 9, 2022

Conditions
Human Immunodeficiency Virus
Interventions
DRUG

Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)

TDF/FTC is a combination anti-HIV medication that contains the drugs tenofovir disoproxil fumarate (300 mg) and emtricitabine (200 mg). Participants will take 2 pills on the first day of the week and one pill per day on the second and third days of the week, according to the dosing schedule of the study arm they are in. Participants will have biologic specimens collected at specific time points until 28 days after the last dose.

Trial Locations (1)

30322

Hope Clinic, Atlanta

All Listed Sponsors
collaborator

Centers for Disease Control and Prevention

FED

lead

Emory University

OTHER

NCT04298697 - Biomarkers for Event-driven PrEP Adherence | Biotech Hunter | Biotech Hunter